echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > J Am Soc Nephrol: Early changes in canagliflozin proteinuria can predict renal and cardiovascular outcomes (CREDENCE study)

    J Am Soc Nephrol: Early changes in canagliflozin proteinuria can predict renal and cardiovascular outcomes (CREDENCE study)

    • Last Update: 2021-09-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The highly anticipated kidney outcome study of the world's first hypoglycemic drug-the results of the CREDENCE study are really shocking! Studies have found that the SGLT2 inhibitor canagliflozin can not only significantly reduce the risk of renal events, but also reduce the risk of cardiovascular events, and at the same time has good safety


    Significantly reduce the risk of renal events, and can also reduce the risk of cardiovascular events, while having good safety

    Background: The relationship between early changes in proteinuria and renal and cardiovascular events is mainly based on the renin-angiotensin inhibitory system


    Methods: Canagliflozin and Diabetic Nephropathy Clinical Evaluation (CREDENCE) trial included 4401 patients with type 2 diabetes and CKD (urinary albumin-creatinine ratio [UACR]>300 mg/g)


    diabetes

    Compared with placebo, canagliflozin reduced the UACR by 31% (95% confidence interval [95% CI], 27% to 36%) at 26 weeks , and significantly increased the possibility of a 30% reduction in UACR (advantage Ratio [OR], 2.


    Canagliflozin reduced UACR by 31% in 26 weeks and significantly increased the likelihood of a 30% reduction in UACR

    Figure 1 From the 26th week, canagliflozin reduced the possibility of proteinuria progressing to nephropathy (group A) and increased the possibility of proteinuria regression (group B)


    Canagliflozin can reduce the probability of proteinuria by ≥30% (OR, 0.


    Every 30% reduction in UACR in the first 26 weeks is independently associated with a reduction in the prognostic risk of primary kidney disease (hazard ratio [HR], 0.


    Every 30% reduction in UACR in the first 26 weeks is independently associated with a reduction in the prognostic risk of primary kidney disease

    Figure 2 Early changes in proteinuria at week 26 were independently associated with (A) comprehensive renal outcome, (B) MACE, and (C) the risk of death from HHF/CV


    The number above each circle represents the rate of occurrence of UACR changes


    In general, in each treatment group, the level of residual proteinuria at week 26 was still a strong independent risk factor for renal and cardiovascular events


    The level of residual proteinuria remains a strong independent risk factor for renal and cardiovascular events

    CONCLUSION: In patients with type 2 diabetes and CKD, the use of canagliflozin can continuously reduce early proteinuria, which is independently related to long-term renal and cardiovascular prognosis


    In patients with type 2 diabetes and CKD, the use of canagliflozin can lead to a sustained reduction in early proteinuria, which is independently related to long-term renal and cardiovascular prognosis


    Original source:

    Original source:

    Oshima M, Neuen BL, Li J, et al.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.